
EU relaxes safety monitoring of CAR-T therapies
The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). The variation includes a reduction in daily hospital safety monitoring for patients following CAR-T cell therapy infusion from… Read More













